BIO CEO: getting payback from investing in investors
This article was originally published in Scrip
Investors in the life sciences are patient, by necessity perhaps rather than by inclination. And yet they still want returns – certainly faster than biotechnology companies have delivered them. But what happens when a company suddenly gets a big win, through a product approval or a big upfront payments or milestones on a deal? Should it reinvest in what it sees as the growth engine of the company or should it dispense value to its supportive shareholders through dividends or other rights?